Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2025)

Historic Net Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 2419.05%.

  • Orchestra BioMed Holdings' Net Margin fell 8561300.0% to 2419.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 2665.05%, marking a year-over-year decrease of 5432900.0%. This contributed to the annual value of 2310.27% for FY2024, which is 5835700.0% down from last year.
  • Orchestra BioMed Holdings' Net Margin amounted to 2419.05% in Q3 2025, which was down 8561300.0% from 2316.15% recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Net Margin high stood at 592.15% for Q1 2022, and its period low was 6385.38% during Q4 2024.
  • For the 4-year period, Orchestra BioMed Holdings' Net Margin averaged around 2220.45%, with its median value being 2051.03% (2024).
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Net Margin crashed by -34498200bps in 2023, and later surged by 16850500bps in 2024.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Net Margin stood at 891.02% in 2022, then crashed by -387bps to 4340.84% in 2023, then plummeted by -47bps to 6385.38% in 2024, then surged by 62bps to 2419.05% in 2025.
  • Its Net Margin stands at 2419.05% for Q3 2025, versus 2316.15% for Q2 2025 and 2160.71% for Q1 2025.